Condition (MeSH)
Color Vision Defects
ClinicalTrials.gov lists 62 trials for Color Vision Defects or a narrower condition beneath it. MeiraGTx UK II Ltd has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
62 of the 62 trials are tagged with Color Vision Defects itself; the rest are tagged with a narrower condition beneath it.
When did Color Vision Defects trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 7 |
| 2024 | 2 |
| 2023 | 5 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 5 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 29 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 40 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Color Vision Defects trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 7 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 26 |
| Observational | 15 |
How many Color Vision Defects trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 9 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 35 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Color Vision Defects trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| MeiraGTx UK II Ltd | 4 |
| Beacon Therapeutics | 3 |
| CENTOGENE GmbH Rostock | 1 |
Which drugs are being tested for Color Vision Defects? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cannabidiol | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Group 1 cannabidiol (CBD) with silicone ointment | 1 |
| IVL3003 | 1 |
| Matched control | 1 |
| CBD Isolate | 1 |
| rAAV.hCNGA3 | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Color Vision Defects trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Uveitis | 5 | 2 |
| Post Procedural Hematuria | 4 | 1 |
| Ectopic pregnancy | 2 | 1 |
| Pneumothorax | 2 | 1 |
| Retinal detachment | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Color Vision Defects? (35)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-associated Achromatopsia. | American journal of ophthalmology | 2023 | Yes |
| Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial. | The British journal of ophthalmology | 2022 | Yes |
| Performance enhancement in color deficiency with color-correcting lenses. | Eye (London, England) | 2022 | Yes |
| Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial. | JAMA ophthalmology | 2020 | Yes |
| Adaptive Changes in Color Vision from Long-Term Filter Usage in Anomalous but Not Normal Trichromacy. | Current biology : CB | 2020 | Yes |
Showing 5 of 35 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.